JP7689955B2 - 抗水痘帯状疱疹ウイルス抗体 - Google Patents

抗水痘帯状疱疹ウイルス抗体 Download PDF

Info

Publication number
JP7689955B2
JP7689955B2 JP2022526794A JP2022526794A JP7689955B2 JP 7689955 B2 JP7689955 B2 JP 7689955B2 JP 2022526794 A JP2022526794 A JP 2022526794A JP 2022526794 A JP2022526794 A JP 2022526794A JP 7689955 B2 JP7689955 B2 JP 7689955B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022526794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500387A5 (enExample
JP2023500387A (ja
Inventor
ホアシン リャオ
ユエミン ワン
ウェイホン チョン
チアチー リー
Original Assignee
チューハイ トリノマブ ファーマシューティカル カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チューハイ トリノマブ ファーマシューティカル カンパニー，リミティド filed Critical チューハイ トリノマブ ファーマシューティカル カンパニー，リミティド
Publication of JP2023500387A publication Critical patent/JP2023500387A/ja
Publication of JP2023500387A5 publication Critical patent/JP2023500387A5/ja
Application granted granted Critical
Publication of JP7689955B2 publication Critical patent/JP7689955B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022526794A 2019-11-11 2020-11-03 抗水痘帯状疱疹ウイルス抗体 Active JP7689955B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911095151.9A CN112778413B (zh) 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体
CN201911095151.9 2019-11-11
PCT/CN2020/126159 WO2021093639A1 (zh) 2019-11-11 2020-11-03 抗水痘-带状疱疹病毒的抗体

Publications (3)

Publication Number Publication Date
JP2023500387A JP2023500387A (ja) 2023-01-05
JP2023500387A5 JP2023500387A5 (enExample) 2023-06-23
JP7689955B2 true JP7689955B2 (ja) 2025-06-09

Family

ID=75749734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526794A Active JP7689955B2 (ja) 2019-11-11 2020-11-03 抗水痘帯状疱疹ウイルス抗体

Country Status (6)

Country Link
US (1) US12491386B2 (enExample)
EP (1) EP4063383A4 (enExample)
JP (1) JP7689955B2 (enExample)
CN (5) CN117106070B (enExample)
PH (1) PH12022551151A1 (enExample)
WO (1) WO2021093639A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117106070B (zh) * 2019-11-11 2024-06-11 珠海泰诺麦博制药股份有限公司 抗水痘-带状疱疹病毒的抗体
CN117683121B (zh) * 2024-01-30 2024-04-16 北京百普赛斯生物科技股份有限公司 抗水痘-带状疱疹病毒抗体及其应用
CN119192349A (zh) * 2024-07-18 2024-12-27 北京市延庆区疾病预防控制中心 用于检测黄连素抗性病毒的试剂及方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2652959B2 (ja) * 1987-12-15 1997-09-10 東燃料株式会社 水痘・帯状疱疹ウイルス感染症の検出薬及び検出方法
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
WO1995031546A1 (en) 1994-04-28 1995-11-23 Scotgen Biopharmaceuticals, Inc. Recombinant human anti-varicella zoster virus antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6528066B1 (en) * 1999-09-14 2003-03-04 University Of Iowa Research Foundation Variant varicella-zoster viruses and methods of use
BRPI0807084A2 (pt) * 2007-02-06 2014-04-29 Ribovax Biotechnologies Sa Anticorpos específicos para o virus varicela zoster
CN102517302A (zh) * 2011-12-28 2012-06-27 中国人民解放军军事医学科学院野战输血研究所 一种重组表达水痘-带状疱疹病毒截短型糖蛋白e的方法及其应用
CN104513813A (zh) * 2013-09-29 2015-04-15 上海满益科技有限公司 一种带状疱疹病毒的制备方法
KR101481362B1 (ko) * 2014-01-28 2015-01-15 연세대학교 원주산학협력단 수두대상포진 바이러스의 당단백질e를 발현하는 인간 세포를 이용한 수두대상포진 바이러스에 대한 면역력 진단 방법
CN105669838B (zh) * 2014-12-04 2020-10-16 厦门大学 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体
JP6367783B2 (ja) * 2015-11-26 2018-08-01 田中貴金属工業株式会社 水痘帯状疱疹ウイルス検出用免疫クロマト分析装置
CN106279378B (zh) * 2016-08-05 2018-06-19 北京市华信行生物科技有限公司 水痘带状疱疹病毒gE抗原及其在检测抗水痘带状疱疹病毒抗体中的用途
KR102028463B1 (ko) * 2016-11-25 2019-10-04 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
CN107760690B (zh) * 2017-10-25 2018-08-28 珠海泰诺麦博生物技术有限公司 一种高通量全人源抗体的制备方法及应用
US11147870B2 (en) * 2018-04-25 2021-10-19 Emory University Specific binding agents to varicella-zoster virus and uses related thereto
CN109085354B (zh) * 2018-07-25 2021-07-23 武汉生命科技股份有限公司 水痘-带状疱疹病毒中和抗体的检测试剂盒及其检测方法
CN117106070B (zh) * 2019-11-11 2024-06-11 珠海泰诺麦博制药股份有限公司 抗水痘-带状疱疹病毒的抗体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIRLEA, M., et al.，JOURNAL OF VIROLOGY，2013年，Vol.87, No.1，pp.415-421，DOI: 10.1128/JVI.02561-12
KAUSMALLY, L., et al.，JOURNAL OF GENERAL VIROLOGY，2004年，Vol.85，pp.3493-3500，DOI: 10.1099/vir.0.80406-0
SULLIVAN, N.L., et al.，JOURNAL OF VIROLOGY，2018年，Vol.92, No.14，e00269(pp.1-18)，DOI: 10.1128/JVI.00269-18
SUZUKI, K., et al.，JOURNAL OF MEDICAL VIROLOGY，2007年，Vol.79，pp.852-862，DOI: 10.1002/jmv.20838

Also Published As

Publication number Publication date
CN117106070B (zh) 2024-06-11
CN117106070A (zh) 2023-11-24
EP4063383A4 (en) 2024-01-17
CN117106069A (zh) 2023-11-24
US12491386B2 (en) 2025-12-09
CN117106071A (zh) 2023-11-24
CN112778413B (zh) 2023-09-22
CN117106071B (zh) 2024-08-27
EP4063383A1 (en) 2022-09-28
JP2023500387A (ja) 2023-01-05
CN117106068B (zh) 2024-04-16
PH12022551151A1 (en) 2023-10-02
CN112778413A (zh) 2021-05-11
WO2021093639A1 (zh) 2021-05-20
US20230192817A1 (en) 2023-06-22
CN117106069B (zh) 2024-06-11
CN117106068A (zh) 2023-11-24

Similar Documents

Publication Publication Date Title
ES2539751T3 (es) Anticuerpo monoclonal capaz de unirse con epítopo discontinuo específico que aparece en la región AD1 de la glucoproteína gB de citomegalovirus humano, y fragmento de unión a antígeno del mismo
JP7689955B2 (ja) 抗水痘帯状疱疹ウイルス抗体
CA3155090A1 (en) Combination of a poxvirus encoding hpv polypeptides and il-2 with an anti-pd-l1 antibody
US20240409620A1 (en) Design and application of fully human antibody for neutralizing respiratory syncytial virus
JP7717194B2 (ja) 呼吸器合胞体ウイルスに対する抗体及びその使用
WO2025246679A1 (zh) 一种广谱中和冠状病毒的抗体及其应用
US20120020980A1 (en) High affinity human antibodies to human cytomegalovirus (cmv) gb protein
CN112004828A (zh) 头颈癌的治疗
JP2024544936A (ja) 組成物
US12404319B2 (en) Methods and compositions for treating yellow fever
WO2022065445A1 (ja) ＳＡＲＳ－ＣｏＶ－２中和抗体又はその断片
JP7653537B2 (ja) 抗水痘帯状疱疹ウイルスの抗体およびその使用
JP2010517557A (ja) 水痘帯状疱疹ウイルスに特異的な抗体
WO2022143815A1 (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
KR20230047179A (ko) 조혈 줄기세포 이식-연관 혈전성 미세혈관병증(hsct-tma)을 치료하기 위한 항-c5 항체의 복용량 및 투여
WO2022127739A1 (zh) 特异性结合SARS-CoV-2的抗原结合蛋白
CN107286237A (zh) 一种抗丙型肝炎病毒抗体的获取以及应用
CN120535614A (zh) 抗RSV pre-F蛋白的抗体及其应用
JP2024044204A (ja) 抗ＳＡＲＳ－ＣｏＶ－２抗体
CN119909167A (zh) 一种包含抗ccr8抗体的药物组合物及其用途
CN115141270A (zh) 特异性结合新型冠状病毒的抗体
WO2021243185A9 (en) Sars-cov-2 binding agents and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230615

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250528

R150 Certificate of patent or registration of utility model

Ref document number: 7689955

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150